Evidence map›Paper›PMID 38339027›Full record

ArticleInternational journal of molecular sciences2024

Recipient Pericardial Apolipoprotein Levels Might Be an Indicator of Worse Outcomes after Orthotopic Heart Transplantation.

Andrea Székely, Éva Pállinger, Evelin Töreki, Mandula Ifju, Bálint András Barta, Balázs Szécsi, Eszter Losoncz, Zsófia Dohy, Imre János Barabás, Annamária Kosztin and 3 more

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 98% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Andrea SzékelyDepartment of Anesthesiology and Intensive Therapy, Semmelweis University, 1085 Budapest, Hungary.
Éva PállingerDepartment of Genetics, Cell- and Immunobiology, Semmelweis University, 1085 Budapest, Hungary.ORCID 0000-0002-5789-0951
Evelin TörekiFaculty of Medicine, Semmelweis University, 1085 Budapest, Hungary.ORCID 0009-0003-1624-7630
Mandula IfjuFaculty of Medicine, Semmelweis University, 1085 Budapest, Hungary.
Bálint András BartaHeart and Vascular Center, Semmelweis University, 1085 Budapest, Hungary.
Balázs SzécsiDoctoral School of Theoretical and Translational Medicine, Semmelweis University, 1085 Budapest, Hungary.ORCID 0000-0003-2341-7389
Eszter LosonczDoctoral School of Theoretical and Translational Medicine, Semmelweis University, 1085 Budapest, Hungary.ORCID 0000-0001-6426-8821
Zsófia DohyHeart and Vascular Center, Semmelweis University, 1085 Budapest, Hungary.
Imre János BarabásHeart and Vascular Center, Semmelweis University, 1085 Budapest, Hungary.ORCID 0000-0002-4404-8730
Annamária KosztinHeart and Vascular Center, Semmelweis University, 1085 Budapest, Hungary.ORCID 0000-0001-6647-2623
Edit I BuzasDepartment of Genetics, Cell- and Immunobiology, Semmelweis University, 1085 Budapest, Hungary.ORCID 0000-0002-3744-206X
Tamás RadovitsHeart and Vascular Center, Semmelweis University, 1085 Budapest, Hungary.
Béla MerkelyHeart and Vascular Center, Semmelweis University, 1085 Budapest, Hungary.
Semmelweis University · HU

Funding

European Union RRF-2.3.1-21-2022-00003Ministry for Innovation and Technology NKFIH-1277-2/2020
6 · The paper itself

Abstract

backgroundEnd-stage heart failure (ESHF) leads to hypoperfusion and edema formation throughout the body and is accompanied by neurohormonal and immunological alterations. Orthotopic heart transplantation (HTX) has been used as a beneficial option for ESHF. Due to the shortage of donor hearts, the ideal matching and timing of donors and recipients has become more important. PURPOSE: In this study, our aim was to explore the relationship between the clinical outcomes of HTX and the cytokine and apolipoprotein profiles of the recipient pericardial fluid obtained at heart transplantation after opening the pericardial sac. MATERIALS AND

methodsThe clinical data and the interleukin, adipokine, and lipoprotein levels in the pericardial fluid of twenty HTX recipients were investigated. Outcome variables included primer graft dysfunction (PGD), the need for post-transplantation mechanical cardiac support (MCS), International Society for Heart and Lung Transplantation grade ≥2R rejection, and mortality. Recipient risk scores were also investigated.

resultsLeptin levels were significantly lower in patients with PGD than in those without PGD (median: 6.36 (IQR: 5.55-6.62) versus 7.54 (IQR = 6.71-10.44);

conclusionOur results indicate that apolipoproteins can facilitate the monitoring of rejection and could be a useful tool in the forecasting of early and late complications.

Indexed as

Heart TransplantationLung TransplantationApolipoproteinsGraft RejectionHumansRetrospective StudiesRisk FactorsTissue DonorsApolipoproteinsapolipoproteinheart transplantationinterleukinorgan recipientprimary graft dysfunction

Identifiers

PMID38339027
PMCPMC10855207
OpenAlexW4391435211

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.